# Harnessing mesenchymal stromal cells for liver disease therapy: from mechanistic discoveries to clinical breakthroughs

## TL;DR

Mesenchymal stromal cells show promise for liver disease therapy by regenerating tissue and modulating the immune system, but challenges remain in standardizing their use.

## Contribution

This review systematically summarizes MSC mechanisms in liver regeneration and highlights emerging strategies to improve their clinical application.

## Key findings

- MSCs secrete HGF, VEGF, and EVs to inhibit HSC activation and degrade fibrotic ECM.
- MSCs modulate the immune microenvironment by promoting M2 macrophage polarization and suppressing T-cell activation.
- Preliminary clinical trials show MSCs are safe and effective in improving survival for end-stage liver disease patients.

## Abstract

Mesenchymal stromal cells (MSCs) demonstrate significant potential in liver tissue regeneration and disease treatment due to their unique immunomodulatory properties, multipotent differentiation capabilities, and paracrine functions. This article provides a systematic review of MSCs’ biological characteristics and mechanistic roles in liver regeneration and summarizes recent clinical advancements and future challenges. Evidence reveals that MSCs exert therapeutic effects by secreting bioactive mediators—including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and extracellular vesicles (EVs)—to inhibit hepatic stellate cell (HSCs) activation, degrade fibrotic extracellular matrix(ECM), and stimulate endogenous hepatocyte proliferation coupled with neovascularization. Their immunomodulatory functions reshape the hepatic immune microenvironment through inducing macrophage polarization toward the anti-inflammatory M2 phenotype, suppressing T-cell activation, and modulating the Th17/Treg balance. Preclinical studies confirm that MSCs effectively restore liver function and reverse fibrosis in diverse liver injury models. Preliminary clinical trials further validate their safety and efficacy, with allogeneic MSC infusion demonstrating survival benefits in end-stage liver disease patients. However, heterogeneity in cell sources, low homing efficiency, and lack of standardized preparation protocols remain major bottlenecks for clinical application. Emerging strategies integrating CRISPR-based gene editing, engineered exosome delivery platforms, and biomaterial-guided localization are imperative to refine targeting specificity and therapeutic precision. This review provides theoretical support and innovative directions for the translational application of MSCs in liver disease therapy.